Microbot Medical Inc. (MBOT) is a commercial-stage medical device company, not an ETF, built around its LIBERTY Endovascular Robotic System. Three credible, current analyst price targets were reviewed. Lucid Capital's Alex Nowak set a $3.00 target with a Buy rating on September 25, 2026, lowering it from $4.00 while arguing investors should focus on the ramp into 2027 rather than near-term numbers. B. Riley Securities' William Wood carries a $4.00 target with a Buy rating. H.C. Wainwright's Raghuram Selvaraju maintains the most optimistic $12.00 target with a Buy rating.
The arithmetic mean of these three figures is roughly $6.33, rounded to a clean $6.30 central target. The $3.00-to-$12.00 range is unusually wide, and the $12.00 figure is a substantial outlier that skews the average upward. All three analysts rate the stock a Buy, but their price objectives imply dramatically different assumptions about how quickly LIBERTY adoption scales. This should not be read as an official published consensus; it is the calculated average of the individual targets identified above.
Shares of MBOT traded near $0.95 as of late October 2026, close to the bottom of a 52-week range of $0.93 to $2.89. The stock has fallen roughly 65% over the past year, giving it a market capitalization of only about $64 million. To reach $6.30, the price would need to rise on the order of 560%, a very large move that would require a fundamental repricing of the business rather than a routine rally.
The company generated its first revenue in the first quarter of 2026 from a Limited Market Release of LIBERTY, and began a Full Market Release on April 13, 2026. Management reported more than 100% sequential growth in both revenue and customer count during the second quarter, with hospital accounts across several U.S. states and a federal healthcare agreement through Lovell Government Services. Still, trailing twelve-month revenue remains in the low hundreds of thousands of dollars against ongoing net losses, so the path to a much higher valuation depends heavily on sustained commercial acceleration and international expansion.
MBOT is trading just above its 52-week low of $0.93, a level that represents near-term support; a sustained break below it would leave the stock at multi-year lows with little chart-based support nearby. The $1.00 level is a nearby psychological barrier. On the upside, the 52-week high near $2.89 is a major resistance zone, and the stock would need to reclaim that area before any move toward the $6.30 target becomes technically plausible. The prevailing long-term trend remains firmly downward.
Analyst price targets generally reflect a research horizon of roughly 12 months, though firms do not always state this explicitly and assumptions can differ. For MBOT, the most important near-term items are the next quarterly results and any commentary on LIBERTY account growth, procedure volume, and recurring orders, followed by progress toward U.S. sales-territory expansion and international commercialization, including a potential European CE Mark. Investors should also watch analyst target revisions, cash position and burn rate, and any new institutional adoption or federal healthcare contracts.
For traders tracking MBOT and similar names, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to follow changing conditions. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market behavior, technical patterns, and AI-driven analysis. Rather than replacing independent research, it helps traders discover opportunities, monitor existing positions, and identify shifting trends more efficiently. Exploring these signals can complement a disciplined, research-based approach to timing entries and exits.
The $6.30 central target is a calculated average of three Buy-rated analyst price targets — not a published consensus — and it sits far above the stock's roughly $0.95 trading level, implying a very large gain of around 560%. The wide $3.00-to-$12.00 range shows that analysts agree on the direction but disagree sharply on magnitude, reflecting genuine uncertainty over how quickly LIBERTY can scale commercially. Early revenue traction, regulatory expansion, and a solid cash position support the bullish case, while a minimal revenue base, persistent losses, competition, and negative price momentum are meaningful obstacles. Whether MBOT reaches $6.30 will depend above all on execution in converting early adoption into sustained, profitable growth — a question no target can answer in advance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MBOT has been loosely correlated with AGPU. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MBOT jumps, then AGPU could also see price increases.
| Ticker / NAME | Correlation To MBOT | 1D Price Change % | ||
|---|---|---|---|---|
| MBOT | 100% | -0.78% | ||
| AGPU - MBOT | 37% Loosely correlated | +5.90% | ||
| QSI - MBOT | 32% Poorly correlated | +6.03% | ||
| AIMD - MBOT | 32% Poorly correlated | -2.24% | ||
| CODX - MBOT | 31% Poorly correlated | -0.82% | ||
| BWAY - MBOT | 30% Poorly correlated | -0.42% | ||
More | ||||
| Ticker / NAME | Correlation To MBOT | 1D Price Change % |
|---|---|---|
| MBOT | 100% | -0.78% |
| Medical/Nursing Services industry (139 stocks) | 4% Poorly correlated | -0.31% |
| Health Services industry (240 stocks) | 3% Poorly correlated | -0.00% |